Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections
- 4 January 2007
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 37 (2), 145-152
- https://doi.org/10.1111/j.1365-2362.2007.01762.x
Abstract
Background Vasopressin has haemodynamic as well as osmoregulatory effects, and reflects the individual stress response. Copeptin is cosynthesized with vasopressin, directly mirroring vasopressin levels, but is more stable in plasma and serum. Both levels are increased in patients with septic shock. Lower respiratory tract infections (LRTI) are a precursor of sepsis. Thus, we investigated circulating levels and the prognostic use of copeptin for the severity and outcome in patients with LRTI. Materials and methods Five hundred and forty-five consecutive patients with LRTI and 50 healthy controls were evaluated. Serum copeptin levels were measured with a new chemiluminescens sandwich immunoassay. Results Of the 545 patients, 373 had community-acquired pneumonia (CAP), 60 acute exacerbations of chronic obstructive pulmonary disease (COPD), 59 acute bronchitis, 13 exacerbations of asthma and 40 other final diagnoses. Copeptin levels were significantly higher in patients with LRTI as compared to controls (P < 0.001) with highest levels in patients with CAP. Copeptin levels increased with increasing severity of CAP, as classified by the pneumonia severity index (PSI) (P < 0.001). In patients who died, copeptin levels on admission were significantly higher as compared to levels in survivors [70.0 (28.8-149.0) vs. 24.3 (10.8-43.8) pmol L-1, P < 0.001]. The area under the receiver operating curve (AUC) for survival was 0.75 for copeptin, which was significantly higher as compared to C-reactive protein (AUC 0.61, P = 0.01), leukocyte count (AUC 0.59, P = 0.01) and similar to procalcitonin (AUC 0.68, P = 0.21). Conclusions Copeptin levels are increased with increasing severity of LRTI namely in patients with CAP and unfavourable outcome. Copeptin levels, as a novel biomarker, might be a useful tool in the risk stratification of patients with LRTI.Keywords
This publication has 35 references indexed in Scilit:
- Circulating levels of soluble triggering receptor expressed on myeloid cells (sTREM)-1 in community-acquired pneumoniaCritical Care Medicine, 2007
- Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failureEuropean Journal of Clinical Investigation, 2006
- Procalcitonin and neopterin correlation with aetiology and severity of pneumoniaJournal of Infection, 2006
- Plasma d-Dimer Levels Correlate With Outcomes in Patients With Community-Acquired PneumoniaChest, 2004
- Regulatory Mechanisms of Corticotropin‐Releasing Hormone and Vasopressin Gene Expression in the HypothalamusJournal of Neuroendocrinology, 2004
- Acute Phase Reactants and Cytokine Levels in Unilateral Community-Acquired PneumoniaRespiration, 2003
- Plasma and platelet vasopressin in essential hypertension and congestive heart failure.Hypertension, 1983
- Greatly Enhanced Pressor Response to Antidiuretic Hormone in Patients with Impaired Cardiovascular Reflexes Due to Idiopathic Orthostatic HypotensionJournal of Cardiovascular Pharmacology, 1980
- The Role of Blood Osmolality and Volume in Regulating Vasopressin Secretion in the RatJCI Insight, 1973
- Development and Clinical Application of a New Method for the Radioimmunoassay of Arginine Vasopressin in Human PlasmaJCI Insight, 1973